User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Monoclonal antibodies for immunotherapy in cancer are a treatment that aids the body’s own immune system to attack tumor cells. In the last 20 years, monoclonal antibody–based treatment for cancer has proven one of the most effective therapeutic strategies for solid tumors, as well as tumors of hematopoietic and lymphoid tissues. Therapeutic antibodies against cancer are used and designed to target cancer surface antigens or to unlock checkpoint inhibitors. This way, the immune response of the human body is initiated to fight tumor cells.
Therapeutic antibody research usually starts with identification and validation of novel targets for immunotherapy.
For subsequent discovery of antibody candidates, B cells are sorted or separated using magnetic beads. The B cells are used either for sequencing of B cell receptors (BCRs) or B cell cultivation and binder selection using the cell culture supernatant.
The final step, antibody functionality, needs to be verified in cell-based assays to determine the mode of action and effector function. Often, additional optimization of antibody candidates and further functionality testing is performed to improve specificity (affinity and avidity), safety (cytokine release, immunogenicity testing), and efficacy (combination therapies, antibody format selection).
Our goal is it to support you at every step of your workflow, to simplify your research, and ensure reproducibility in your data.
Our therapeutic antibody discovery research solutions support:
Target identification:
Antibody discovery:
Functionality testing:
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.
View details
